



**Clinical Trial Title :** «Assessment of Metabolic and pathological Response to Treatment with Radio-chemotherapy (RCT) and Immunotherapy (ImT) before Surgery in locally advanced Esophageal and gastro-esophageal junction cancer: ARTemIS-Eso, a three-level, open-label, phase I-II study »

**EudraCT Number :** «2016-000935-42»

**Protocol Number :**« IJB-GASTON-002-ARTEMIS-Eso »

**Study name :** « ARTemIS-Eso »

**NO or PARTIAL RESULTS FOR THIS TRIAL**

**(I) Accrual**

- The trial is terminated before any subject was recruited.
- The trial is terminated whereas \_\_\_\_\_ subjects/ \_\_\_\_\_ were recruited.

**(II) Reasons**

- The positive opinion by the Ethics Committee in charge of the trial is not granted or is irrevocably revoked.
- The authorisation by the Competent Authority of the Member State concerned in charge of the trial is not granted or is irrevocably revoked.
- The sponsor became or was declared insolvent or a petition in bankruptcy has been filed against it or it is dissolved.
- Early end of the scientific collaboration with one or more partners.
- Early termination due to safety.
- Discontinuation or change of the strategic direction of the development of the medicinal product(s) that the sponsor wanted to study.
- Trial logistics or limited trial population, as defined by the inclusion/exclusion criteria, leading to a poor recruitment.
- Publication of other clinical trials which changed the therapeutic landscape and rendered our trial design obsolete.
- Publication of other clinical trials already demonstrating the clinical interest of our trial and rendered our trial obsolete.